The addition of entinostat, a histone deacetylase inhibitor, to exemestane has demonstrated improved progression-free survival (PFS) in hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) following endocrine therapy failure in the EOC103A3101 randomi...
Jia-Ni Wang, Qing-Yuan Zhang, Xi-Chun Hu et al.· Signal Transduction and Targ...· 0 citations
Sacituzumab tirumotecan (sac-TMT) is a novel anti-trophoblast cell-surface antigen 2 antibody-drug conjugate and has been approved for second-line and subsequent treatment of metastatic triple-negative breast cancer (TNBC) in China. This post-hoc exploratory study aims to further characterize the safety profile of sac-...
Y. Fan, Q. Ouyang, Y. Yin et al.· Breast Cancer Research· 1 citation
Glucuronide prodrug strategies may enhance target specificity and reduce the toxicity of PARP inhibitors, but no clinical evaluation has been performed. We evaluated TSL-1502, a novel glucuronide prodrug of a PARP inhibitor, in a randomized, open-label, phase 2 study at 28 sites in China (NCT05420779). Eligible patient...
B. Lan, Faliang Xu, Tao Sun et al.· Signal Transduction and Targ...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.